- Status:
- Topic prioritisation
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Rationale:
- The NICE-Wide Prioritisation Board met on 09 October 2025 and concluded that an evaluation would not be appropriate for this product. The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers concluded that the clear rationale to not evaluate this product is due to commissioning under the NHS England commissioning medicines for children in specialised services policy being appropriate with mercaptamine hydrochloride being a paediatric extension of an existing NHSE commissioning policy. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12261
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
For further information on how we select topics for development, please see our page about topic prioritisation